ADMA Biologics Inc (ADMA) Q3 2026 Earnings Call Highlights: Asceniv Surge Drives Margin ...
ADMA Biologics Inc (ADMA) posted 13% sequential revenue growth to $141.1 million with gross margin jumping to 71%, prompting an increase in full-year 2026 adjusted EBITDA and net income guidance. Related Stocks: ADMA ,